8-K: Clene Inc. Presents Biomarker Data for ALS NDA Submission

Clene Inc. announced new biomarker analyses from its CNM-Au8 trials, showing a correlation between NfL biomarker response and improved survival and function in ALS patients, which will be included in its upcoming NDA submission for accelerated approval.

Summary

• Clene Inc. announced new analyses of its CNM-Au8 clinical trials for ALS, focusing on the neurofilament light chain (NfL) biomarker.
• These analyses indicate that patients treated with CNM-Au8 whose NfL levels declined or stabilized experienced significantly longer survival and better functional outcomes compared to control groups.
• The findings will be included in Clene's planned New Drug Application (NDA) seeking accelerated approval from the FDA.
• The FDA previously acknowledged NfL's prognostic value in ALS and its potential as a surrogate endpoint for accelerated approval.
• Specific results include a 74% lower risk of death at 12 months for CNM-Au8 30 mg treated patients with NfL response compared to controls in the HEALEY trial, and a 38% lower risk of death over the full follow-up period.
• Functional improvements were observed in daily function (ALSFRS-R) and breathing capacity (Slow Vital Capacity; SVC) among NfL responders.
• A causal analysis, requested by the FDA, identified a 41% lower risk of death in predicted NfL responders treated with CNM-Au8 30 mg versus controls.
• CNM-Au8 has demonstrated a consistent safety and tolerability profile with over 1,280 participant-years of treatment, including over 1,100 in ALS, with no serious adverse events assessed as related to the drug.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the company is presenting new biomarker data to support its NDA submission, which could lead to accelerated approval. However, the data is post hoc and exploratory, and the FDA has not yet made a determination on the surrogate endpoint.

Positives

• New biomarker analyses showing a correlation between NfL biomarker response and improved survival and function in ALS patients treated with CNM-Au8.
• These findings are intended to support Clene's planned New Drug Application (NDA) for accelerated approval.
• The FDA has previously acknowledged the prognostic value of NfL in ALS and its potential as a surrogate endpoint.
• CNM-Au8 treated patients with NfL decline or stabilization showed a 74% lower risk of death at 12 months in the HEALEY trial (p=0.0124) and a 38% lower risk of death over the full follow-up period (p=0.037).
• Significant improvements in daily function (ALSFRS-R, p=0.032) and breathing capacity (SVC, p=0.003) were observed in NfL responders.
• A causal analysis indicated a 41% lower risk of death in predicted NfL responders treated with CNM-Au8 30 mg versus controls (p=0.026).
• CNM-Au8 has a consistent safety and tolerability profile with over 1,280 participant-years of treatment, and no serious adverse events have been assessed as related to the drug.
• The planned Phase 3 confirmatory trial, RESTORE-ALS, will prospectively evaluate the NfL biomarker relationship.

Negatives

• The biomarker analyses presented are post hoc and exploratory.
• Neither the HEALEY nor RESCUE-ALS trials met their prespecified primary efficacy endpoints.
• No adjustment was made for multiple comparisons in the presented analyses, and reported p-values are nominal.
• The analyses were not powered for a direct statistical comparison between NfL strata.
• The FDA has not yet made a determination regarding the acceptability of NfL reduction as a surrogate endpoint for CNM-Au8.
• The company acknowledges that subsequent events and developments may cause their views to change regarding forward-looking statements.

Risks

• The post hoc and exploratory nature of the biomarker analyses may not be predictive of results in future trials.
• Regulatory agencies' actions could affect the initiation, timing, and progress of clinical trials and marketing approval.
• Clinical trial results may not support further development or marketing approval, potentially leading to additional costs or delays.
• The company has a limited operating history and may need additional funding for operations and to complete development and commercialization.
• Forward-looking statements are subject to numerous risks and uncertainties, and actual results may differ materially.

Future Outlook

Clene plans to submit its New Drug Application (NDA) for accelerated approval in early Q4 2026, supported by the presented biomarker analyses. The company is also designing a Phase 3 confirmatory trial, RESTORE-ALS, to prospectively evaluate the NfL biomarker relationship.

Management Comments

• "ALS is a heterogeneous disease, and it matters that a biomarker signal, NfL decline or stabilization, marks the patients in whom CNM-Au8 appears to be providing the greatest benefit."
• "In the HEALEY analyses, we were able to go a step further: using pre-treatment characteristics alone, we could identify the patients likely to show NfL response, and the treatment benefit was concentrated in exactly that group."
• "The FDA's accelerated approval of another drug for SOD1-ALS established that a reduction in NfL can be reasonably likely to predict clinical benefit in a defined ALS population."
• "Observing the NfL biomarker-to-clinical-benefit relationship replicated in two independent trials, and NfLs prognostic value confirmed in more than 2,000 patients who never received CNM-Au8, is exactly the kind of evidence that gives us confidence in what were submitting to the FDA."

Industry Context

StockSavvy.ai notes that the use of biomarkers like NfL to support accelerated approval pathways is a growing trend in the pharmaceutical industry, particularly for neurodegenerative diseases where traditional clinical endpoints can be slow to manifest. The FDA's acceptance of NfL as a surrogate endpoint for another ALS drug (tofersen) sets a precedent, but each drug's submission is evaluated on a program-by-program basis.

Comparison to Industry Standards

• The FDA's acceptance of NfL reduction as a surrogate endpoint for tofersen in SOD1-ALS demonstrates an industry-accepted pathway for accelerated approval based on biomarker data.
• The prognostic value of NfL in ALS is established, with analyses in over 2,000 patients (APST, ANSWER ALS) showing a 10% NfL decline associated with a 6-10% lower risk of death, aligning with general understanding of NfL's role in disease progression.
• The company's planned Phase 3 trial, RESTORE-ALS, which will prospectively stratify patients by NfL levels, aligns with industry best practices for confirmatory trials following accelerated approvals.

Stakeholder Impact

• Shareholders: Potential for accelerated approval could lead to significant value creation if the NDA is successful, but risks remain due to the exploratory nature of the data and regulatory hurdles.
• Patients and Patient Advocacy Groups: Positive news regarding potential accelerated approval for an ALS treatment, offering hope for improved survival and function.
• FDA: The agency will evaluate the submitted biomarker data to determine if it meets the criteria for accelerated approval.
• Healthcare Providers: Will be interested in the efficacy and safety data supporting CNM-Au8 as a potential treatment option for ALS.

Next Steps

• Include biomarker analyses in the planned New Drug Application (NDA) submission for accelerated approval.
• File the NDA with the FDA in early Q4 2026.
• Design and initiate the Phase 3 confirmatory trial, RESTORE-ALS, to prospectively evaluate the NfL biomarker relationship.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' rating. While the presentation of biomarker data to support an NDA for accelerated approval is a positive step, the data is post hoc and exploratory, and the FDA has not yet confirmed NfL as a valid surrogate endpoint for CNM-Au8. Significant regulatory hurdles remain, and the company's ability to achieve commercial success is not yet assured. Investors should await further FDA feedback and the outcome of the confirmatory trial.

Keywords

ALS, Amyotrophic Lateral Sclerosis, CNM-Au8, Biomarker, NfL, Neurofilament Light Chain, NDA Submission, Accelerated Approval